The latest lifestyle, fashion and travel trends

He is one of the most googled names in beauty, and she, one of the most prominent figures in fashion.

It was therefore a fitting match for Victoria Beckham to join forces with Augustinus Bader the notoriously publicity-shy director of stem cell biology and cell technology at the University of Leipzig for her first foray in to skincare.

Bader became a household beauty name in February 2018, after the launch of his cult-product The Cream caused convulsions of desire to ripple throughout the beauty industry thanks to its ultra-hydrating and restorative qualities.

And so when looking for a scientific collaborator to join her on her endeavour in to skincare, it seemed a natural fit for the two to merge theircomplementingareas of expertise.

The Cell Rejuvenating Priming Moisturizer (Victoria Beckham Beauty)

Cue the result of the pairing: Victoria Beckham Beautys Cell Rejuvenating Priming Moisturizer.

The moisturiser is the new-and-improved iteration of the Morning Aura Primer Beckham launched as part of her collaboration with Este Lauder in 2016.

The product, which Beckham has re-developed with the help of 59-year-old Bader, is a multifunctional cream thatclaims to prime, impart a glow and also to repair.

Commenting on the collaborative beauty effort, Beckham took to her Instagram page to note: It has been a dream to develop, with Augustinus, a priming moisturizer that works to improve the health of my skin and gives that fresh, natural glow that I love.

Meanwhile Bader said: "It was an honour to collaborate with Victoria for her first Skin launch. I'm excited to share some of our skincare benefits in this product. It's the first product of its kind to care for your skin cells while also preparing your skin for makeup application."

A celebrity facialist has revealed VB's 9-step daily skincare routine

This marks the first skincare product 45-year-old Beckham has launched under her beauty line, which she debuted to critical-acclaim in September, alongside the brands co-founder, Sarah Creal.

Victoria Beckham Beauty has the tagline Luxury Performance, Clean Beauty, and is refusing to pigeonhole itself as just a beauty brand, instead referring to itself as clean beauty movement.

Cell Rejuvenating Priming Moisturizer costs 92 for 30ml and launches tomorrow exclusively at victoriabeckhambeauty.com and augustinusbader.com.

Continued here:
Everything you need to know about Victoria Beckhams first skincare product launching tomorrow - Evening Standard

Skin Stem Cells Comments Off on Everything you need to know about Victoria Beckhams first skincare product launching tomorrow – Evening Standard | November 18th, 2019

Gallant Stem Cell Therapy For Dogs is one of the product companies to be featured on Shark Tank Season 11 Episode 8. The story behind the birth of Gallant Stem Cell Therapy For Dogs is pretty interesting. Here are some of the unknown facts about Gallant and its founders, Aaron Hirschhorn.

Aaron Hirschhorn is the founder and former-CEO of the popular dog-sitting marketplace DogVacay. Aaron is a noted entrepreneur with more than 20 years of experience in building companies and investing in them. DogVacay app was launched in 2013 and Aaron managed to raise $47 million from his erstwhile investors.

Aaron was the finalist in the Ernst & Young Entrepreneur of the Year Award 2016. In April 2017, Aarons DogVacay app merged with Rover.com and eventually went on to become a $1 billion pet services marketplace.

Trouble struck Aarons life when he suffered a massive back injury and was forced to undergo stem cell treatment which yielded amazing results to his surprise. Aaron, being an ardent dog lover wondered why this cutting-edge medical technology of stem cell transplants cannot be applied to dogs.

As a result, Gallant was born in the middle of 2018. According to Gallant, Your pups stem cells haveincredible healing power. Extract and store these powerful cells during your pets spay/neuter, so that you can unleash their potential when your best friend needs it most.

Ever since its inception, the mission of Gallant stem cell therapy is to help pets live a healthier life and make use of the epic technology of stem cell therapy in saving the lives of tons of dogs.

Dogs enter their senior years around 7 and begin feeling the effects of aging as early as 4! Traditional methods of treatment for injury and age-related conditions are expensive and can have harmful side effects. Stem cells are incredible natural healers. However, up to 99% of stem cells are lost over time due to aging. This forms the bottomline of Gallants business problem.

Gallant raised $7 million investment in August 2019.

https://gallant.com/

From the moment you entrust Gallant with your dogs stem cells, were actively invested in their long-term health and well-being. Working in tandem with you and your veterinarian, we will collect and store these powerful cells now, so down the road we can help to treat the most common health problems your dog may face. We will also update you on new and potentially life-changing treatments as they become available.

Pick your pups stem cell storage plan you dont have to have a spay/neuter procedure scheduled yet! You can always add that in later. Our proprietary process requires no additional training, so any veterinarian you trust to alter your dog is qualified. Ahead of your dogs spay/neuter, we will connect with your vet and send our collection kit directly to their office.

2. Collect

On the big day, we align with your vet before the procedure and arrange for a courier. During your dogs spay/neuter procedure, your veterinarian will take out the stem cell-rich reproductive tissue they would normally discard into the collection kit.

3. Preserve

Once the tissue is received by our scientists, we send confirmation to both you and your veterinarian. Your dogs tissue is first inspected for quality before isolating the stem cells. The stem cells are then counted and frozen in liquid nitrogen to preserve their potency in our secure, state-of-the-art laboratory. Once this process is complete, you and your veterinarian will be notified that your pets stem cells are safely stored. The cells are then monitored by our team to ensure they stay perfectly preserved.

4. Treat

Your pets stem cells are at the ready to be sent to your veterinarian if/when treatment is needed. Treatments are out-patient procedures and cost about $300. A stem cell procedure is not painful to your pet and does not require anesthesia to administer.

Gallants stem cell therapy is receiving a lot of exciting reviews online. The therapy has been successful in saving scores of dogs with conditions like osteoarthritis, skin conditions, chronic dry eye.

Gallant is offering a $395 off discount for using the code SHARKTANK

How did Gallant fare in Shark Tank Season 11? What did the Sharks have to tell about it? Did Gallant Get a Deal on Shark Tank? More information to be updated soon in this post.

Continue reading here:
Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts - TheNewsCrunch

Skin Stem Cells Comments Off on Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts – TheNewsCrunch | November 18th, 2019

Global oncology drugs market was estimated to be US$ 119 billion in 2018 is expected to reach US$ 350.01 billion by 2027, growing at an estimated CAGR of 12.7% over the forecast period.

Cancer is a disease, which involves the abnormal growth of cells that results in the formation of a tumor. However benign tumors are not cancers. The abnormal tumor cells have the tendency to spread to other local tissues and may also spread to different parts of body through blood and lymphatic system. Different types of cancers such as lung cancer, colorectal, breast cancer, and others are predominant among the populace. Treatment of cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage.

Request For Sample Copy of This Report:https://www.absolutemarketsinsights.com/request_sample.php?id=273

The detailed research study provides qualitative and quantitative analysis of the global oncology drugs market. The market has been analyzed from demand as well as supply side. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Key Findings of the Report:

Enquiry Before Buying This Report:https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=273

Key Market Segments of Oncology drugs market are:

By Indication

Oncology drugs Market By Treatment

Oncology drugs Market By Geography

For more information ask our experts@https://www.absolutemarketsinsights.com/reports/Oncology-Drugs-Market-2019-2027-273

About Absolute Markets Insights:Contact Us:Company: Absolute Markets InsightsContact Name: Shreyas TannaPhone: +91-740-024-2424Email id:sales@absolutemarketsinsights.comWebsite:https://www.absolutemarketsinsights.com

Read this article:
Oncology drugs market is expected to grow at a CAGR of 12.7% over the forecast period owing to rising number of pipeline cell-therapy products, says...

Skin Stem Cells Comments Off on Oncology drugs market is expected to grow at a CAGR of 12.7% over the forecast period owing to rising number of pipeline cell-therapy products, says… | November 18th, 2019

Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.

Click to copy

CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) ( http://www.internationalstemcell.com ) (ISCO or the Company), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019.

As we mentioned before we completed the enrollment of the Phase I Parkinsons disease clinical trial and currently involved in reorganizing our revenue-generating subsidiaries. We expect that we will see positive results of this reorganization next year. - commented Andrey Semechkin, PhD., CEO and Co-Chairman of ISCO.

Year-to-Date Financial Highlights

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCOs core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( http://www.lifelinecelltech.com ), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe Harbor Statement

Statements pertaining to anticipated developments, expected results of clinical studies, progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates,) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the companys business, particularly those mentioned in the cautionary statements found in the companys Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share data and par value) (Unaudited)

Assets

Cash

Accounts receivable, net

Inventory, net

Prepaid expenses and other current assets

Total current assets

Non-current inventory

Property and equipment, net

Intangible assets, net

Right-of-use assets

Deposits and other assets

Total assets

Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)

Accounts payable

Accrued liabilities

Operating lease liabilities, current

Related party payable

Advances

Warrant liability

Total current liabilities

Long-term deferred rent

Operating lease liabilities, net of current portion

Total liabilities

Commitments and Contingencies

Series D Redeemable Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and

outstanding, with liquidation preference of $4,300 at September 30, 2019

Stockholders' Equity (Deficit)

Series B Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, 250,000

issued and outstanding, with liquidation preferences of $423 and $411 at September 30, 2019 and

December 31, 2018

Series D Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and

outstanding, with liquidation preference of $4,300 at December 31, 2018

Series G Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, issued and

outstanding, with liquidation preference of $5,000 at September 30, 2019 and December 31, 2018

Series I-1 Convertible Preferred stock, $0.001 par value, 2,000 shares authorized, 814 issued and

outstanding, with liquidation preferences of $814 at September 30, 2019 and December 31, 2018

Series I-2 Convertible Preferred stock, $0.001 par value, 4,310 shares authorized,

issued and outstanding with liquidation preference of $4,310 at September 30, 2019 and December 31, 2018

Common stock, $0.001 par value, 120,000,000 shares authorized, 7,533,083 and 6,933,861 shares

issued and outstanding at September 30, 2019 and December 31, 2018

Additional paid-in capital

Accumulated deficit

Total stockholders' equity (deficit)

Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

International Stem Cell Corporation and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited)

Revenues

Product sales

Total revenues

Expenses

Cost of sales

Research and development

Selling and marketing

General and administrative

Total expenses

Loss from operations

Other income (expense)

Change in fair value of warrant liability

Interest expense

Miscellaneous income

Total other income (expense), net

Net income (loss)

Net income (loss) applicable to common stockholders

Net income (loss) per common share-basic

Net income (loss) per common share-diluted

Weighted average shares-basic

Weighted average shares-diluted

Contacts:

International Stem Cell Corporation

Russell A. Kern, PhD

Phone: 760-940-6383

Email:

SOURCE: International Stem Cell CORP

View source version on accesswire.com:

Visit link:
International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019 - Associated Press

Skin Stem Cells Comments Off on International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019 – Associated Press | November 17th, 2019

This product gave our columnist her best-ever skin. Read on

The Sunday Times,November 17 2019, 12:01am

This is one of those ding-ding-ding with a knife on a glass occasions. Obviously I review products I love and recommend from the heart every week, but equally obviously, not every single one is necessarily a life-changer. My personal list of the skincare products I would never again be without is not especially long. However, I currently have the best skin I have ever had in my entire life, including during periods when I paid much more attention to it and had regular facials, microdermabrasions, peels and so on. Hence the glass dinging.

Decree is another line by a doctor, in this case a Dr AJ Sturnham, who is a GP with a special interest in dermatology and aesthetics. The idea is that the line

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

The rest is here:
India Knight on the facial serum that transformed her skin - The Times

Skin Stem Cells Comments Off on India Knight on the facial serum that transformed her skin – The Times | November 17th, 2019

Victoria Beckham has called on scientist Augustinus Bader, who created a 205 face cream that celebrities rave about, to develop a hi-tech skincare product that claims to supercharge your complexion

The Sunday Times,November 17 2019, 12:01am

Do you remember when Victoria Beckham launched a product called Morning Aura? It was part of her first make-up collection for Este Lauder in 2016 and sent fans into a frenzy, selling out in record time.

In September, VB launched her own beauty brand, Victoria Beckham Beauty, with the help of Sarah Creal the former head of global make-up marketing and product development at Este Lauder, and the woman who worked closely with her on that first beauty collection. And now they are returning to Morning Aura, but better, Beckham says, when we speak on the phone.

But this isnt the usual new-bottle-same-formula reboot: she has teamed up with Professor Skincare himself, Augustinus Bader, one of the most googled names in beauty. Bader shot

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

More:
Victoria Beckham on testing products on David and Harper's concerns for sustainability as she launches new skincare - The Times

Skin Stem Cells Comments Off on Victoria Beckham on testing products on David and Harper’s concerns for sustainability as she launches new skincare – The Times | November 17th, 2019

BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.

On November 13, 2019, BioRestorative Therapies, Inc. (the Company) held a Special Meeting of Stockholders (the Special Meeting). The following is a listing of the votes cast for and against, as well as abstentions, with respect to the matters voted upon at the Special Meeting. At the Special Meeting, the Companys stockholders (i) approved an amendment to the Companys Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 150,000,000 to 300,000,000, (ii) approved amendments to the Certificate of Incorporation of the Company, and authorized the Board of Directors of the Company to select and file one such amendment, to effect a reverse stock split of the Companys common stock at a ratio of not less than 1-for-2 and not more than 1-for-100, with the Board of Directors of the Company having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Companys Board of Directors in its discretion (the Reverse Stock Split Proposal), which Reverse Stock Split Proposal revises the reverse stock split ratio approved by the Companys stockholders on May 30, 2019 and (iii) authorized the Board of Directors of the Company, in its discretion, to reduce the number of shares of common stock authorized to be issued by the Company in proportion to the percentage decrease in the number of outstanding shares of common stock resulting from the reverse split (or a lesser decrease in authorized shares of common stock as determined by the Companys Board of Directors in its discretion).

(d) Exhibits.

3.1 Certificate of Amendment of Certificate of Incorporation of the Company

About BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX)

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.

Excerpt from:
BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive

Skin Stem Cells Comments Off on BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders – Market Exclusive | November 17th, 2019

If you're a science fiction enthusiast, then chances are, you already have a clear picture of what the future holds for humanity. Be it space travel, robots, or some weird means of extradimensional communication, sci-fi films have given us a glimpse of future technologies and events one way or another. In fact, each decade, sci-fi movies' futuristic predictions keep growing more accurate.

RELATED:Ranked: 10 Scariest '90s Sci-Fi Movie Monsters

By the 2000s, some of them have already gotten a little too prophetic and hauntingly precise. Needless to say, they are definitely worth watching for their predictions alone. So, we present you with 10 sci-fi films from the 2000s that got the future right in one or more aspects. These masterpieces have not only entertained us but also prepared us for the coming years.

Crime is one of the favorite subject matters of sci-fi media because it allows for creative twists in the otherwise exhaustive genre.Minority Report(2002)and its Pre-crime system is a good example. It's basically a prediction of who will commit crimes or become criminals based on their psychological background and allows authorities to stop crim before they even happen.

As it turns out, Pre-crime is not entirely far-fetched as a law-enforcement system. Japan (who'd have thought?) has something quite similar but less advanced, from A.I. cameras that can detect shoplifters before they do the deed to a "crime analytics" system which predicts where crime will happen. Their police force only began using such tech during this decade.

A.I. Artificial Intelligenceis one of the most philosophical sci-fi films of all time and doesn't shy away from questioning the nature of humanity and what makes us human. In that regard, it paints a rather familiar scene of the future where humans are using robots for prostitution.

RELATED:10 Sci-Fi Movies That Will Make You Think As Much As Inception

In the film, this becomes apparent as soon as Jude Law's robot character, Gigolo Joe, gets introduced. You can probably guess what he does for a living. You'll either be pleased or weirded out to know that bots like Gigolo Joe exist today. There are now official sex dolls who can talk and even give compliments, there's even a brothel full of dolls. Who knows what a few more years of robotics and primal human urges can bring?

Many things inWall-Efrom 2008 are now starting to become true today. Well, perhaps they were already true back then, but they're definitely becoming a lot more apparent today. We're talking about the Earth becoming a giant landfill, advertisements everywhere there's a breathing human being, drivable chairs, and of course, rising obesity rates.

Oh, there's also the fact that certain Governments and even corporations are most likely already looking for a way out of Earth (andto Mars) before things get too messy. In a way,Wall-Eis already happening and we really should be more alarmed now, shouldn't we?

You've probably never heard ofThe Islandbefore and that's due to the film not having the best marketing. In any case,The Islandis about a man who struggles to fit in at an isolated compound he lives in. He soon discovers that everyone was a clone of someone else and that they were merely being harvested for their organs to treat the social elite.

RELATED:10 Best Sci-Fi Movies of the '90s, According to IMDb

Surprise, surprise, there have been scientific and medical breakthroughs about the exact same thing. Scientists have been able to use human cloning to create stem cells that were used to regenerate the skin cells of a 75-year-old man. Further studies and developments are needed and we're still stuck with experimenting on pigs at the moment.

I, Robot was a cinematic flop but was still impressive enough to get its own meme culture more than a decade later. Critics often hailed it as a rip-off ofBlade Runner but in hindsight,I, Robot was a little more radical in how it gave us a picture of future societies. In the film, corporations ruled everything, with automation and A.I. replacing many jobs, making lots of humans unemployed.

Sadly, robots might actually soon take our jobs. We're not just referring to blue-collar work being replaced by heavy machinery; A.I. is learning fast and might take over some administrative jobs and basically everything that requires routine and repetition. It's time to re-evaluate your career options.

It's more romance than sci-fi butEternal Sunshine of the Spotless Mindhas that one plot device (metaphorical or not) which makes quality as science fiction. That would be the memory deletion procedure which a mad neuro-surgeon in the film invented. It allows him to delete people's memories of other people, basically selective amnesia with consent; the first application the filmmakers thought for that technology was moving on from a heartbreak.

RELATED:10 Worst Sci-Fi Movies, According To IMDb

Turns out, there are more practical uses for such a procedure in the real world. Scientists have successfully erased some traumatic memories for mice back in 2013 by locating a gene. They do hope to apply the same procedure to ease the mental pain of patients with post-traumatic stress disorders (PTSD), rather than just for couples with breakup difficulties.

Unfortunately,The Matrixwas released back in 1999, which makes it a year short of qualifying as a 2000s movie. Still, it had sequels and an animated anthology spin-off calledThe Animatrixthat basically explored the same ideas. One notable technology thatThe Matrixfranchiseprophesized (see what we did there?) is virtual reality.

The protagonists ofThe Matrixfranchise basically plug themselves into computers to sort of act as viruses that can bring down their machine enemies. To an extent, we do have this tech today in the form of VR headsets. It's not as immersive as sticking a huge needle into your spine, of course.

Marvel'sIron Manback in 2008 kicked off many great and influential things that we enjoy today and among those is a rekindled interest in robotics and military engineering. Apart from Robert Downey Jr. as Tony Stark, the biggest star inIron Manwas his self-sustaining and relatively compact armor; it's basically the equivalent of a whole country's army controlled by one man.

RELATED:10 90s Sci-Fi Masterpieces Youve Probably Never Seen

We don't have anything that advanced today; it's practically impossible at the moment with our limited resources and lack of further frontal lobe development but the U.S. Army is trying nonetheless with its exo-suit. These allow soldiers a better physical edge on the battlefield. They did try to re-create something more similar to the Iron Man suit but failed and ended up wasting millions of dollars.

The idea of visiting, recording, and manipulating dreams was popularized in Hollywood by films likeInception; however,Inception's primary inspiration was a Japanese anime film calledPaprika(2006), which also explored the same concept of entering, viewing, and interfering with dreams.

These days, such a feat is no longer limited to daydreaming; in 2011, a team of scientists at UC Berkeley was able to view someone else's dream. The scientists recordedthe subjects'brain activity and then translated the whole thing into a video. There were also scientists in Kyoto, Japan who managed to predict another person's dream into a picture which was 60 percent accurate. No more forgetting your dreams sooner or later.

You're probably tired of seeingChildren of Menin movie lists over and over again but it can't be helped, it's such a revelatory masterpiece that we can learn a lot from it. It's more modern dystopia than sci-fi, meaning most of what the film foresaw are political and socio-economic struggles similar to what we're experiencing today.

Apart from the rapidly declining birth rate which is happening to a certain country today,Children of Menalso painted a picture of a disturbing immigration crisis where people of wartorn countries are rushing like animals to the only countries with functioning governments left in the world. Oh, and resources are also in decline and everyone's out for themselves.Sounds eerily familiar.

NEXT:10 Times 90s Sci-Fi Movies Predicted The Future

Tags:iron man,the matrix,sci-fi

View original post here:
10 Times 2000s Sci-Fi Movies Predicted The Future | ScreenRant - Screen Rant

Skin Stem Cells Comments Off on 10 Times 2000s Sci-Fi Movies Predicted The Future | ScreenRant – Screen Rant | November 17th, 2019

By Justin A. Varholick, Ph.D.

As we grow older theres an impending fear that we will slowly, but surely, begin to lose our vision. This slow loss of vision is clinically dubbed low vision and impacts more than 39 million Americans, costs $68 billion annually in direct health care costs, and is only growing in our population as baby boomers enter the at-risk age of 65 and older. Magnifiers can often be used to help people with acute issues of low vision, but are often inconvenient and frustrating. More serious issues of low vision such as cataracts, age-related macular degeneration, glaucoma, and diabetic retinopathy require advanced treatment and surgery. For example, cataracts can be improved or reversed by removing the cloudy lens and replacing it with an artificial one. Such surgeries are not always ideal, or convenient, and further contribute to the already hefty direct health care costs. But, a recent breakthrough by Japanese scientists, in correcting blurry vision, might reverse this bleak future.

Old cells can become new againOur story begins around the mid-20th century, in 1958. A young and aspiring scientist, named John Gurdon, was studying frogs at the University of Oxford in England. Not everyone thought Gurdon would end up actually becoming a scientist. In his early days his school master thought such a career was far-fetched for Gurdon. Indeed, he ranked last in his Biology class out of 250 students. Yet despite such poor grades, Gurdon found himself studying frogs at Oxford and earning a doctoral degree in Biology. And his studies would surprisingly lead to a breakthrough in vision, and likely many other issues in human health, like Parkinsons Disease, heart disease, and spinal cord injury.

At the time Gurdon was trying to test an age-old theory on cell development. Many scientists before him discovered that cells the smallest unit of life begin without a clear fate in the early stages of an embryo. Then as the cell develops, their fate becomes more clear. They become cells of the heart, of the brain, the kidneys, the stomach, the spinal cord, or the eyes. But they cannot go back to a time when they had no fate, or specialization. The cells can only develop in one direction, from no destiny, to a clear path, then to a mature adult cell; like one found in the heart. But you just cant take a heart cell and start the process over, maybe turning it into a brain cell.

In disagreement with this theory, Gurdon did a simple experiment. He knew that a tadpole has more adult cells than a frog egg. A tadpole has gills, a heart, eyes, etc., while a frog egg simply does not. So, he cut open the tadpole and removed a single cell from the intestine; an intestinal cell. He then cut open the intestinal cell and removed its nucleus; the seed of the cell carrying all the DNA. Very carefully, he did the same with the frog egg, and finally replaced the nucleus of the frog egg with the nucleus of the intestinal cell. According to the age-old theory, the intestinal nucleus should stop normal development of the frog egg. But thats not what happened.

Instead, the new frog egg continued to develop normally, becoming a tadpole that later became an adult frog. Gurdon thought this was unbelievably odd, and so did everyone else in science. After many more experiments doing the exact same procedure (i.e., replication), it seemed that what he saw was a real, replicable fact. For some reason the nucleus of the intestinal cell was able to reverse itself to have no fate and slowly develop into any other adult cell. The seed from the intestine somehow could become the seed of a heart, brain, kidney, or even an eye cell and of course, an intestinal cell too.

After many more experiments testing the same theory, on many more animals, it seemed the theory was true, but it just didnt work for mammals. Given that the same effect could not be repeated in a mammal, some believed this discovery did not apply to humans. But they were wrong.

The discovery of induced pluripotent stem cellsAlmost 45 years later, around the start of the millennium, Shinya Yamanaka and Kazutoshi Takahashi began running experiments that would translate Gurdons findings to humans. Born after Gurdons findings were already published and well known, Yamanaka and Takahashi grew up in a world in which the fact that old cells can become new again was widely knowna solid foundation for further hypotheses, experiments, and discovery. So, the scientists set out to do what no one had before: turn adult skin cells of mice into new cells without a clear fate.

Yamanaka, the lead investigator of the study, shared a similar early history with Gurdon. He first became a medical doctor in Japan but was frustrated by his inability to quickly remove small human tumors taking over an hour rather than the typical 10 minutes. Senior doctors gave him the nickname Jamanaka, a Japanese pun for the word jama meaning obstacle. He then found himself earning a PhD in pharmacology and becoming a post-doctoral scientist, but spent more time caring for mice than doing actual research. Frustrated again, his wife suggested he just become a practicing physician. Despite her advice, Yamanaka applied to become an Assistant Professor at Nara Institute of Science and Technology, in Japan, and won everyone over with his fantastical ideas of investigating embryonic stem cells; the cells without a clear fate.

Then the persistence paid off when Yamanaka with his assistant, Takahashi discovered how to induce adult skin cells from mice to return to an embryonic, or stem cell, state without a clear fate. They began their experiments knowing that gene transcription factors proteins that turn genes on and off were responsible for keeping embryonic cells in a state without a clear fate. They thought that by turning specific genes on and off with these factors, they could turn back time and make an adult cell embryonic again. So, they tried many different combinations of gene transcription factors and ultimately discovered that 4 specific ones were enough to induce an adult skin cell to a mouse to become an embryonic cell. Because these re-newed embryonic cells, or stem cells, originally came from adult cells they came up with a new name, induced pluripotent stem cell. Broken down, induced pluripotent stem cells means that the cell was induced to become pluripotent pluri meaning several, like plural, and potent meaning very powerful (and stem meaning to have the ability to turn into any cell in the body).

These induced pluripotent cells were thought to be very powerful indeed and scientists across the globe were excited by this great discovery. They had visions of taking a persons skin or blood, forming them into induced pluripotent cells, and then using them to grow a new liver or new parts of the brain. Laboratories across the world confirmed the results by repeating the experiment.

Human stem cells Just repeating the experiments in mice, or frogs, was not enough. They needed to begin making induced pluripotent stem cells from humans. Enter scientists from the University of Wisconsin-Madison. The lead scientist, James Thomson was already well known for deriving primate embryonic cells from rhesus monkeys in 1995 and the first human embryonic cell line in 1998. In fact, Thomsons accomplishment of isolating embryonic cells from monkeys was the first sound evidence that it was possible to do the same for humans. Such discoveries placed him on the forefront in ethical considerations for research using human embryos and the most obvious scientist to lead the path toward making induced pluripotent stem cells from humans.

Thomsons team made the first human derived induced pluripotent stem cells from adult skin, with Yamanaka as a co-scientist. They followed the same general principles set by Yamanaka, who did the procedure with mouse skin cells. Importantly to Thomson, this discovery helped to relieve some ethical controversy with using human embryos to make human stem cells. By being able to induce adult human skin to become pluripotent stem cells, much research on human stem cells could be done without human embryos albeit research with human embryos remains necessary.

Yet more important to the discussion at hand, the ability to induce human skin to become pluripotent stem cells placed us on the edge of a breakthrough. With some clinical trials in humans, the fantasy of growing a new liver, heart, or eye was more a reality than ever before.

The start of human trials In 2012, around the time both Gurdon and Yamanaka were presented with the Nobel Prize in Physiology and Medicine for their work leading to induced pluripotent stem cells, human clinical trials were beginning in Japan. The first clinical trial was for age-related macular degeneration, an eye condition leading to blindness. Unfortunately, this trial was quickly terminated when Yamanaka and his team identified small gene mutations in the transplanted induced pluripotent stem cells from the first patient. Although the procedure did cure the patient of macular degeneration, these small gene mutations worried the scientists because they could lead to tumor development.

But recently with the introduction of an inducible suicide gene that can signal cells with abnormal growth to die, human trials are starting up again. In October of 2018, Japanese scientists began trials with Parkinsons disease, a brain disease related to a shortage of neurons producing dopamine. Scientists took cells from the patients, made them into induced pluripotent stem cells, guided them to develop into dopamine producing cells, and then deposited them in the dopamine centers of the brain through surgery. The outcome is promising since similar procedures in monkeys have been successful.

Other trials in Japan have also started, including spinal cord injury and one for replacing the cornea of the eye. Early results replacing damaged corneas with induced pluripotent stem cells, thereby correcting blurry vision, were just announced at the end of August. Although it will take more patients and safety checks before all humans can get induced pluripotent cells to correct their damaged eyes, malfunctioning brains, or broken spinal cords, Takahashi the post-doctoral scientist working with Yamanaka thinks it might happen as early as 2023. So, it looks like that in our lifetime we just might be able to stay young and enjoy retirement because of great breakthroughs in animal research.Note, EuroStemCell is a great resource for learning more about the ethics and research currently being done with stem cells derived from human embryos.

Like Loading...

Related

See the rest here:
BREAKTHROUGH: Her vision was getting worse, then animal research made things clear - Speaking of Research

Skin Stem Cells Comments Off on BREAKTHROUGH: Her vision was getting worse, then animal research made things clear – Speaking of Research | November 14th, 2019

Wound healing is complex. Injured tissues undergo a multi-phase process from hemostasis to tissue remodeling. And defensin plays a role.

Basically, it's your natural mechanism for healing a wound, and it stimulates a specific stem cell, the LGR6+ stem cell, according to Greg Keller, M.D., who presented Clinical Data with Defensins at the Global Aesthetic Conference in Miami earlier this month.

After activation, LGR6+ stem cells physically migrate into the basal layer of the skin and create a new epidermis, and eventually, new, younger-acting skin, says Dr. Keller.

In her Cosmeceutical Critique of The role of defensins in treating skin aging, Leslie Baumann, M.D., writes, LGR6+ stem cells, which are dormant until they are activated to respond to damage, are stimulated by defensins.1

She effectively summarizes their role in anti-aging as:

Old fibroblast and keratinocytes are sluggish and lazy. Old cells do not hear signals as well as younger cells. LGR6+ stem cells repopulate the epidermis with new, young keratinocytes. Defensin stimulates LGR6+ stem cells. The defensin/LGR6+ pathway plays a role in keratinization. Using topical defensin can improve the skins appearance.

Theoretically, says Dr. Keller, hair follicles provide a way for defensins to enter the skin to activate the LGR6+ pathway, but We wanted to actually measure wrinkles and quantify how much better the skin was in terms of pore size, oiliness, wrinkles, and the like.

So he, Amy Taub, M.D., Vivian Bucay, M.D., Jay Williams, Ph.D, and Darius Mehregan, M.D., conducted a participant- and investigator-blinded, placebo-controlled, multi-center study with the defensin-containing DefenAge 3-step system (Progenitor Biologics) that includes the 2-Minute Reveal Masque, 24/7 Barrier Balance Cream and 8-in-1 BioSerum, on 44 women, 41-71 years of age with skin types I to V.2

References:

1. Taub A, Bucay V, Keller G, Williams J, Mehregan D. Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation. J Drugs Dermatol. 2018;17(4):426-441.2. Bauman L. The role of defensins in treating skin aging. Cosmeceutical Critique. MDedge Dermatology. April 1, 2018. Accessed November 13, 2019. Available at: https://www.mdedge.com/dermatology/article/161149/aesthetic-dermatology/...

See more here:
Defensins and the dermis - Dermatology Times

Skin Stem Cells Comments Off on Defensins and the dermis – Dermatology Times | November 14th, 2019

Macau is the ultimate setting for some high octane fun this weekend with the return of the annual Macau Grand Prix, now heading into its 66th year. As the city is pulsing with adrenaline, there are plenty of gastronomic highlights as well as the creme de la creme of lifestyle experiences to keep on your radar. Here are all the best events to check out in Macau this month.

When: 16 November

Price: MOP501,000 from Macau Grand Prix

The annual mecca for motorsports is back: Macau opens its venerated 6.2km Guia Circuit as the annual Macau Grand Prix edges into its 66th edition. Veteran and young drivers alike are descending on the SAR for the ultimate glory across three headlining races the Formula 3 Macau Grand Prix, the FIA GT World Cup, and the FIA WTCR, also known as the Macau Guia Race. Sundays Grand Prix finale will have all eyes on some of the worlds best racers such as F3 world champion Dan Ticktum as he returns to the spotlight to vie for his third consecutive win at Macau; alongside newcomers such as David Schumacher, nephew of seven-time Formula 1 winner Michael.

If youre not watching from the Grand Stand or the thrilling Lisboa Bend Stand, for a vantage point to catch all the action in comfort, youll want to head to the Grand Lapa for its annual Grand Prix Live BBQ Buffet all weekend from 1617 November, which will also be broadcasting live on mega screens.

More info here.

When: 30 November1 December

Price: HK$5881,688 from MGM

Actor-turned-chef Nicholas Tse is lending both sides of his talents to this unique food and music festival held for the very first time in Macau. MGM is hosting two nights of unmissable concerts by Tse and fellow Canto-pop stars JW, Joey Yung, rock group Mr., Angela Hui, Chinese singer Liu Junge, Singaporean songstress Joanna Dong, and Macanese band MFM. Alongside two nights of performances, Chef Nic has also partnered with MGMs most eminent chefs to deliver mouthwatering menus of local delicacies, as well as live demonstrations featuring popular chef collaborations from his TV show brought to life. Dont miss this rare chance for dinner and a show.

MGM COTAI, 1/F Roof Terrace, Avenida Da Nave Desportiva, Cotai, Macau, +853 8806 8888

When: Through 29 February, 2020

Theres nothing better than a steamy hot pot dinner during the cooler months: Head to Broadway Macau for a foodie extravaganza of Macanese delicacies for its fourth Hot Pot Street promotion for an eclectic taste of the Cantonese winter tradition. The hotels flagship food street introduces 20 authentic varieties of hot pots showcasing a full spectrum of broths, casseroles and winter warmers from an array of international cuisines, paired with spreads of fresh seafood, organic produce, and premium beef from all over the world.

Broadway Macau, Avenida Marginal Flor de Lotus, Cotai, Macau, +853 8883 3338

The latest hot opening adding to the epicurean haven that is Taipa Village is none other than Barcelona, an innovative new Spanish restaurant and bar by chef Hector Costa Fernandez. Dishing up modern tapas and refreshed Spanish classics, Barcelona is a three-storey venue with a stylish ground floor bar and chefs table overlooking an open kitchen, a first-floor dining room inspired by its eponymous city, and an exotic rooftop bar offering views over the vibrant entertainment area below.

Barcelona, 47 Rua dos Clerigos, Taipa, Macau, +853 2845 5168

Facialist to the stars Margie Lombard, founder of Margys of Monte-Carlo brings an exclusive spa experience to Morpheus this autumn. Famed for her gold mask facial, Margys upgrades her ultimate skin rejuvenating treatment with a new platinum mask treatment that is solely available at Morpheus Spa. Book into one of only six suites for an exalted 110-minute session of pampering with the Prestige Facial with Platinum Mask (MOP3,980), and watch as the chainmail-like platinum mask does its work to retexturise skin for an unbeatable lasting radiance. The Platinum mask is also available as a 20-minute add-on (MOP2,500) together with Margys prized bespoke Stem Cell Illuminating Facial (MOP3,800), which uses a new serum featuring the regenerating power of Swiss Apple stem cells.

Morpheus Spa, 35/F, Morpheus, City of Dreams, Estrada do Istmo, Macau, +853 8868 3098

When: 16 November and 25 January, 2020

Price: MOP28,888 + 10 percent service charge

City of Dreams two-Michelin-starred Alain Ducasse by the eponymous legend is home to some of the most exclusive French haute cuisine menus in this part of the world as it is, but this autumn the restaurant is presenting two unprecedented wine-pairing dinners, billed as featuring some of the greatest vintages of all time. On 16 November, guests can look forward to five rare vintages from Domaine de la Romane-Conti, as well as a prize draw to win a bottle of 1997 Grands-chzeaux. On 25 January next year, guests can also book in as they celebrate Bordeauxs landmark 1982 vintage with a horizontal tasting of Chteau Pichon Longueville Comtesse de Lalande, Chteau Mouton Rothschild, Chteau Margaux, Chteau Cheval Blanc and Chteau Lafite Rothschild and have the opportunity to win a bottle of 1982 Chteau Margaux. Priced at MOP28,888 per person, these exclusive wine dinners will feature a tailor-made seven course menu and kick off with a glass of Dom Prignon 2009, followed by five rare vintages and Grand Crus. Make your reservation by email to adam@cod-macau.com or call +853 8868 3432.

Alain Ducasse, Level 3, Morpheus, City of Dreams, Estrada do Istmo, Macau, +853 8868 3432

Price: MOP7801,280

The St. Regis Macaos Iridium Spa has unveiled its newest treatment, a session that combines both mindful and physical therapy by allowing guests to create their own blended diffuser scents and body scrubs. After spending time learning more about the healing powers of aromatherapy, the guest is given a 45-minute massage and body treatment thats sure to melt away all the tensions of the mind and body.

Iridium Spa, 38/F, St. Regis Macao, S/N, Estrada do Istmo, Macau, +853 8113 4949

Originally posted here:
What to do in Macau: The 66th Grand Prix, $28888 wine dinners and more - Lifestyle Asia

Skin Stem Cells Comments Off on What to do in Macau: The 66th Grand Prix, $28888 wine dinners and more – Lifestyle Asia | November 14th, 2019

REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimers blood diagnostic Lymphocyte Proliferation Test (LymPro Test) with amyloid PET neuroimaging at Leipzig University in Germany (the LymPro PET 2). Topline results are expected before the end of the first quarter of 2020.

Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimers disease, as confirmed with amyloid PET neuroimaging and other Alzheimers disease biomarkers. LymPro measures cell cycle dysregulation in peripheral lymphocytes. The top-line data, announced in July 2019, revealed a strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216). Breakthroughs academic collaborators at the Leipzig University then expanded enrollment of that study to include an additional cohort of 20 subjects (LymPro PET 2) to confirm the strong relationship seen from LymPro PET 1. The data from both LymPro 1 and LymPro 2 will be published together in a peer-reviewed journal in 2020.

LymPro is a unique immune system-based Alzheimers blood test, said Dr. Herman Weiss, President & CEO of Todos. LymPro could prove to be a major breakthrough for Alzheimers disease diagnosis by measuring cell cycle dysregulation and amyloid, together, conveniently as part of a blood workup in routine clinical practice. The therapeutic field in Alzheimers has begun to see some renewed hope based upon recent Aducanumab data announced by Biogen that is directly related to the amyloid hypothesis, as well as conditional approval by the National Medical Products Administration in China for the first new Alzheimers drug in over 20 years, called Oligomannate from Shanghai Green Valley Pharmaceuticals, that is based on gut-brain biology of the microbiome and its effects on the immune system. We believe this renewed optimism and broadening of pathophysiological hypotheses relevant to Alzheimers disease being evaluated in the clinic significantly increases the scope for LymPro pharma services collaborations and begins to refine LymPros clinical utility profile for primary care physicians as strategies to correct cell cycle dysregulation emerge.

About Alzheimer's DiseaseAccording to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually.Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050.

About Dr. Arendt's Research at Leipzig UniversityDr. Thomas Arendt is Professor of Neuroscience at Leipzig University where he runs the Paul Flechsig Institute of Brain Research. He has a 30-year record in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and made several seminal contributions to therapeutic concepts of Alzheimer's disease, including stem cell therapy and modulating tumor suppressor genes. In the early 1980's, he was involved in identifying the degeneration of the cholinergic system in Alzheimer's disease laying the basis for today's only available treatment. He is one of the pioneers of the "cell-cycle theory" of Alzheimer's disease, which he developed towards a diagnostic and therapeutic concept.

Story continues

About Breakthrough Diagnostics, Inc.Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test, a diagnostic blood test for Alzheimers disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.

The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

About Todos Medical Ltd.Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancers influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The companys two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test, a blood test for diagnosing Alzheimers disease.

For more information, the content of which is not part of this press release, please visithttp://www.todosmedical.com

About Amarantus Bioscience Holdings, Inc.Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Companys 80.01%-owned subsidiaryBreakthrough Diagnostics, Inc.,currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimers blood diagnostic LymPro Test from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise and Parkinsons diagnostic NuroPro. Amarantus entered into a joint venture agreement withTodos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos. The transaction is expected close before the end of the first quarter of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc., a healthcare data-generating technology company that specializes in biomarker assay services that target multiple areas of oncology. Avant provides precision oncology data through its TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders, initially for breast cancer, to over 70 FDA-approved drug treatments.

AMBS 50%-owned subsidiaryElto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimers aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquiredCutanogen Corporationfrom Lonza Group in 2015. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriners Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS wholly-owned subsidiary,MANF Therapeutics Inc.owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinsons disease. MANF was discovered by the Companys Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Amarantus has entered into a binding letter of intent to license the therapeutic assets from Elto Pharma, Cutanogen and MANF Therapeutics to Emerald Organic Products.

Forward-looking StatementsCertain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Investor and Corporate Contact:Kim Sutton GolodetzLHA Investor RelationsSenior Vice President (212) 838-3777kgolodetz@lhai.com

Todos Corporate ContactDaniel HirschTodos MedicalInvestor RelationsEmail:Dan.h@todosmedical.comPhone: (347) 699-0029

Amarantus Investor and Media Contact:Gerald CommissiongPresident & CEOOffice: 650-862-5391Email: gerald@amarantus.com

Read the original here:
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimers Blood Test Relationship with Amyloid PET - Yahoo Finance

Skin Stem Cells Comments Off on Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimers Blood Test Relationship with Amyloid PET – Yahoo Finance | November 14th, 2019

Engineering | Health and medicine | News releases | Population Health | Research | Science | Technology

November 12, 2019

Microscopy image showing the cytoskeleton within neurons, which are differentiating from induced pluripotent stem cells.UC San Francisco

With a $106 million gift from the Weill Family Foundation, UC Berkeley, UC San Francisco and the University of Washington have launched the Weill Neurohub, an innovative research network that will forge and nurture new collaborations between neuroscientists and researchers working in an array of other disciplines including engineering, computer science, physics, chemistry and mathematics to speed the development of new therapies for diseases and disorders that affect the brain and nervous system.

A 2016 study by the Information Technology & Innovation Foundation estimated that, in the U.S. alone, neurological and psychiatric disorders and diseases including Alzheimers; Parkinsons; anxiety and depression; traumatic brain injury and spinal cord injury; multiple sclerosis; ALS; and schizophrenia carry an economic cost of more than $1.5 trillion per year, nearly 9 percent of GDP.

The gains in knowledge amassed by neuroscientists over the past few decades can now be brought to the next level with supercomputers, electronic braincomputer interfaces, nanotechnology, robotics and powerful imaging tools, said philanthropist Sanford I. Sandy Weill, chairman of the Weill Family Foundation. The Neurohub will seize this opportunity by building bridges between people with diverse talents and training and bringing them together in a common cause: discovering new treatments to help the millions of patients with such conditions as Alzheimers disease and mental illness.

Complementing the strengths of UCSF, Berkeley and the UW, the Weill Neurohub will draw on the expertise and resources of the 17 National Laboratories overseen by the Department of Energy, which excel in bioengineering, imaging, and data science. In August 2019, the Weill Family Foundation and the DOE signed a Memorandum of Understanding creating a new publicprivate partnership. The partnership is exploring the use of the Departments artificial intelligence and supercomputing capabilities, in conjunction with Bay Area universities and the private sector, to advance the study of traumatic brain injury, or TBI, and neurodegenerative diseases.

Secretary of Energy Rick Perry, who has spearheaded the creation of an AI and Technology Office during his tenure at DOE, said that the vision for the Weill Neurohub dovetails with his own mission to make publicly funded AI and supercomputing resources more widely accessible to advance scientific discovery. We are on the cusp of great discoveries that could transform our approach to TBI, Alzheimers disease and other neurological and psychiatric disorders, and easing access to the world-class computational power of our National Laboratories to initiatives like the Weill Neurohub is a win-win for science and the public sector and, eventually, for patients.

As many neurological disorders, such as dementia, are associated with aging, the costs of these unmet medical needs are expected to increase significantly in the coming years. California, with the largest aging population in the U.S., with one in five residents reaching age 65 or older in the next decade, faces particularly formidable challenges, said Gov. Gavin Newsom.

Every day, millions of people in California, the nation, and the world are facing the uncertainty of neuro-related diseases, mental illness and brain injuries, and collaboration between different disciplines in science, academia, government and philanthropy is critical to meet this challenge. Together, we must accelerate the development and use cutting-edge technology, innovation and tools that will advance research and practical application that will benefit people across the world and for generations to come, said Newsom. I want to thank Sandy Weill and his wife, Joan, for their amazing work, kindness, dedication and commitment to philanthropic causes, especially when they open doors, bridge gaps, and make innovation and collaboration possible to advance causes that can truly have an impact on peoples quality of life.

Sanford and Joan Weill.UC San Francisco

The Weill Neurohub will enable the three universities to work together on these pressing problems. For example, the UW and UCSF, renowned research universities with long traditions of excellence in basic neuroscience research, also have federally sponsored Alzheimers Disease Research Centers, or ADRCs. Through the Weill Neurohub, members of the UWs ARDC, part of the UW Medicine Memory and Brain Wellness Center, and UCSFs ADRC, led by the UCSF Memory and Aging Center, will collaborate with top neurodegeneration researchers at Berkeley.

The Weill Neurohub will provide funding for faculty, postdoctoral fellows, and graduate students at the UW, Berkeley and UCSF working on cross-disciplinary projects, including funding for high-risk/high-reward proposals that are particularly innovative and less likely to find support through conventional funding sources. But the bulk of the Weill Neurohubs funding will support highly novel cross-institutional projects built on one or more of four scientific pillars that Weill Neurohub leaders have deemed priority areas for answering the toughest questions about the brain and discovering new approaches to disease: imaging; engineering; genomics and molecular therapeutics; and computation and data analytics.

The Weill Neurohub may seek additional academic, corporate and philanthropic partners to harness resources collaboratively, better scale research and development efforts, share information and data and create partnerships to make breakthroughs faster and at a lower cost than the current paradigm allows.

Relevant examples of interdisciplinary or cross-institutional neuroscience projects now underway at UCSF, Berkeley and/or the UW include:

This gift expands on the unique vision and mission of the UCSF Weill Institute for Neurosciences, established in 2016 with a $185 million gift from the Weill Family Foundation and Joan and Sandy Weill whose giving to the neuroscience community now exceeds $300 million said UCSFs Dr. Stephen Hauser, the Robert A. Fishman Distinguished Professor of Neurology and Weill Institute director.

The UCSF Weill Institute set out to break down walls between the clinical disciplines of neurology, neurosurgery and psychiatry, and also bring these clinical specialties together with the basic neurosciences, said Hauser. Now, with the Weill Neurohub, were going even further: eliminating institutional boundaries between three great public research universities, and also other disciplinary walls between traditional neuroscience and non-traditional approaches to understanding the brain. By embracing engineering, data analysis and imaging science at this dramatically higher level areas in which both Berkeley and the UW are among the best in the world neuroscientists on all three campuses will gain crucial tools and insights that will bring us closer to our shared goal of reducing suffering from brain diseases.

Hauser will serve as one of two co-directors of the new Weill Neurohub along with Berkeleys Ehud Udi Isacoff, the Evan Rauch Chair of Neuroscience. Together with Tom Daniel, the Joan and Richard Komen Endowed Chair and professor of biology at the UW, they will serve on the Weill Neurohubs Leadership Committee.

In the Weill Neurohub, the emphasis will be on technology to enable discovery of disease mechanisms, and thus development of novel treatments and early detection of neurologic diseases, to allow intervention before conditions become severe, said Isacoff, who heads Berkeleys Helen Wills Neuroscience Institute. The technologies include next-generation neuroimaging and therapeutic manipulations ranging from brain implants to CRISPR gene editing, with major efforts in machine learning and high-speed computation. I think these three campuses can succeed in this joint mission in a way that no others can the combined expertise this group brings to the table, especially when you bring in the National Labs, really is unparalleled.

Tom Daniel, the Joan and Richard Komen Endowed Chair and professor of biology at the University of Washington.University of Washington

The UWs Daniel added, The Weill Neurohub brings together three outstanding public institutions, each with a deep commitment to bridge boundaries between science, engineering, computer science and data science to address fundamental problems in neuroscience and neural disorders. To my knowledge, this is a nationally unique enterprise drawing on diverse approaches to accomplish goals no single institution could reach alone, as well as seeding and accelerating research and discovery.

Neuroscientists have made huge strides in understanding the brain in the 30 years since President George H. W. Bush designated the 1990s as the Decade of the Brain, and subsequently through the National Institute of Healths ongoing BRAIN Initiative, first announced by President Obama in 2013. But treatments for neurological and psychiatric diseases have lagged far behind those for other common afflictions, such as cardiovascular disease and cancer.

Much of the lack of progress on neurological and psychiatric disease is due to the unparalleled complexity of the nervous system, in which hundreds of billions of nerve cells and support cells form as many as 100 trillion connections in intricate three-dimensional networks throughout the brain and spinal cord. The Weill Neurohubs leaders believe reaching beyond conventional approaches is essential to grappling with this complexity.

Despite amazing advances in neuroscience, new therapies are not reaching patients with mental illness and neurological disorders nearly as quickly as they have for heart disease and cancer. And in addition to the terrible personal toll these illnesses exact on patients and their families, they also have a massive impact on our healthcare system and on the global economy, said Joan Weill, president of the Weill Family Foundation. Our goal, through the broad and multifaceted approach of the Weill Neurohub, is to begin to change that.

Read the original:
New Weill Neurohub will unite UCSF, UC Berkeley, UW in race to find new treatments for brain diseases - UW Today

Skin Stem Cells Comments Off on New Weill Neurohub will unite UCSF, UC Berkeley, UW in race to find new treatments for brain diseases – UW Today | November 12th, 2019

BURLINGAME, CA / ACCESSWIRE / November 12, 2019 / Humanigen, Inc., (OTC PINK:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation chimeric antigen receptor T cell (CAR-T) and other cell therapies, today announced that two abstracts supporting development of its next generation EphA3-CAR-T program, built on the backbone of ifabotuzumab, the company's proprietary Humaneered anti-EphA3 monoclonal antibody, have been accepted for presentation at the 2019 annual meeting of the Society for Neuro-Oncology (SNO) being held November 20-24, 2019 in Phoenix, AZ.

While CAR-T therapy has revolutionized the treatment landscape for hematological malignancies, its efficacy remains limited in solid tumors. The majority of CAR-T therapies targeting solid tumors have focused on cell surface receptors expressed on tumor cells. However, given the heterogeneity of surface receptor expression on solid tumors and the difficulty of navigating the immunosuppressive stromal microenvironment, strategies to target tumor neovasculature and tumor stromal cells are emerging. Targeting non-transformed, tumor neovasculature and tumor stroma cells may overcome antigen loss and may modulate the suppressive TME. EphA3, an oncofetal antigen, is selectively expressed in tumor neovasculature and tumor stromal cells in brain cancers and other solid tumors making it a novel target for CAR-T development.

The phase I clinical study, led by Prof. Hui Gan and Prof. Andrew Scott from the Olivia Newton-John Cancer Research Institute in Melbourne, Australia, was funded by the Cure Brain Cancer Foundation. The study used radiolabeled ifabotuzumab followed by sequential positron emission tomography (PET) imaging to determine biodistribution, frequency of in situ EphA3 expression and quantitative tumor uptake of ifabotuzumab. The preliminary results include data from eight patients who have been enrolled to date. PET/computed tomography (CT) imaging showed that ifabotuzumab is effectively delivered across the blood-tumor barrier and accumulates specifically at the tumor site in all patients treated to date with no observed normal tissue uptake. Magnetic resonance imaging (MRI) scans showed predominant T2/FLAIR changes, consistent with the treatment effect of ifabotuzumab on tumor vasculature. Treatment emergent adverse events were readily managed with increased premedications after the first occurrence. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi6/5619490?redirectedFrom=fulltext.

Professors Gan and Scott stated "Our results show that ifabotuzumab is safe and very effective at targeting the tumor. We are also excited that there are early indications that ifabotuzumab may help to control disease growth in some patients."

Using a single chain variable region fragment of ifabotuzumab, a second generation CD28 co-stimulated CAR construct was developed. Using primary patient derived GBM cell lines, the EphA3 CAR-T demonstrated specific and potent anti-tumor activity. Data from in vivo and combinatorial CAR-T experiments will be reported during the oral presentation scheduled on Friday, November 22, 2019 at 4:40pm. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi88/5619352?redirectedFrom=fulltext.

"These results indicate for the first time that targeting EphA3 with CAR-T cells is feasible, efficacious, and represents a novel therapeutic strategy for solid tumors" stated Dr. Cameron Durrant, CEO of Humanigen. "Our EphA3-CAR-T program as another pillar in our developing cell therapy pipeline. While we continue to develop our GM-CSF neutralization platform with Kite, we are also busy building next generation CAR-T therapies with our combinatorial GM-CSF gene-editing platform and our other CAR-T programs focused on novel tumor targets", Dr. Durrant continued.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. For more information, visit http://www.humanigen.com

Story continues

About the Olivia Newton-John Cancer Research Institute

The Olivia Newton-John Cancer Research Institute is a leader in the development of experimental and breakthrough cancer treatments. We investigate and develop treatments for cancers of the breast, lung, skin, prostate, liver, gastrointestinal tract and brain. Our researchers and clinicians are running more than 120 clinical trials, giving patients access to potential new treatments including immunotherapies and personalized medicine.

Located in Heidelberg, Victoria, Australia, the Institute is integrated within the ONJ Centre, with research laboratories only metres away from where patients are cared for and receive treatment. This inspires and enables the rapid translation of scientific discovery into clinical trial of new, better, cancer treatments.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for future development of lenzilumab to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Black Horse Capital and its affiliates owning more than 50% of our outstanding common stock, including their ability to control the company; our lack of profitability and need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Media:Chris Bowe(646) 662-7628cbowe@humanigen.com

SOURCE: Humanigen, Inc.

View source version on accesswire.com: https://www.accesswire.com/566037/Humanigen-Announces-Two-Abstracts-Accepted-at-the-2019-Annual-Meeting-of-the-Society-for-Neuro-Oncology-including-Oral-Presentation-on-its-Next-Generation-EphA3-CAR-T

See the article here:
Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next...

Skin Stem Cells Comments Off on Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next… | November 12th, 2019

One tweetfest tapped into our pervasive shame over store-bought salad: "Almost left the grocery store without buying a bag of spring mix to throw, unopened, into the garbage in two weeks."

It doesn't have to be that way. You can learn to choose the freshest fruits and veggies, clean and store them properly and be assured at least a few more days of usable life.

Let's start with our "universal" waste disgrace -- store-bought spring mix. First, check out the best-by or expiration date (it may help to pull from the bottom or back of the stack to get a date further in the future). Then before you buy, inspect. Are any wet or bruised leaves visible? If so, keep looking.

Once you've bought the freshest and driest salad you can find, you'll want to open it as soon as you get home and, with freshly washed hands, transfer the leaves into a large bowl. As you put those leaves back into the plastic container, remove any bruised or spoiled pieces and discard. Just as a bad apple will more quickly rot the barrel, those leaves will shorten the life of the rest of your salad greens.

Trouble keeping spinach fresh in those large, cheap containers? The same trick applies.

Greens by the bunch

If you buy lettuce by the head or greens by the bunch from the farmer's market or grow your own, they may contain sand or dirt as well as bacteria.

Immersing the leaves in a bowl of tap water for a few minutes can loosen up any dirt. Again, don't use the dirty sink to soak.

But be careful with the water temperature -- and this applies to all vegetables and fruits -- it should be about the same temperature as the produce you are washing.

If immersed in water more than 10 degrees Fahrenheit colder than the produce, it will create a vacuum -- due to air cells contracting within the produce -- and pull in wash water, Ghimire said.

"If the wash water is contaminated, anything in that water, including foodborne pathogens, will be internalized or sucked into the produce," he explained, adding that it's likely to happen at the weak points of the stem and blossoms.

"Hot water is not desired as it would increase the temperature of the produce and decrease shelf-life," Ghimire said.

After washing, spin the leaves in a salad spinner. If you're storing, pat dry with paper towels before putting them into perforated or vented plastic bags and putting them into the crisper section of your refrigerator.

"I rinse and dry lettuce leaves or raw veggies, such as celery, broccoli, and cauliflower, wrap them in paper towels, and store them in plastic bags or in plastic containers lined with paper towels," Drayer added.

And don't forget to wash your salad spinner after about three uses -- if it will fit into the dishwasher, that's a great option to sanitize it.

Veggies

"Select veggies in season for maximum freshness, flavor, and nutritional value," said Drayer. And they cost less when in season, an extra bonus.

"Firmness, shape, color, texture of skin, and aroma are keys to selecting the freshest produce," Ghimire said. "For example, a fresh broccoli would be firm, closed, dark-green florets, and tender stalks. Yellowing green-colored heads of broccoli are over mature."

Once they are home, you'll want to take them out of the plastic bags if the bags aren't breathable or perforated.

"Produce are alive even after harvest and they continue to breath and transpire even on your counter top," Ghimire said.

Brush off any loose dirt before storing.

Storing veggies depends on the type. Many do fine in vented plastic bags or plastic containers. Others may fare better in brown paper bags.

"As brown paper bags absorb moisture and are breathable, they would better work for produce like mushrooms and strawberries that have a short shelf-life," Ghimire said.

Potatoes and onions are also good choices for paper bags, Ghimire said. Because brown paper restricts the ability of light to penetrate, onions and potatoes won't turn as green as they would in clear plastic bags; it also reduces the chance of "hollow heart" in potatoes -- the black center you sometimes see which is caused by a lack of oxygen.

Some vegetables need to be kept out of the 40-degree Fahrenheit refrigerator to stay fresh and tasty. You probably know that tomatoes should be stored on the countertop.

But did you know the same is true for basil, cucumbers, eggplants, onions, peppers, potatoes, pumpkins, squash and sweet potatoes?

Cucumbers, for example, "may develop chilling injury if stored below 50 degrees Fahrenheit for more than two or three days," Ghimire said. "Produce kept outside the fridge should be stored in a cool, dry and well ventilated space."

Wash before eating, of course, by using a vegetable brush on hard varieties like potatoes and carrots before peeling; more sensitive veggies can be rubbed briskly between your hands under running water.

Fruits

Again, selecting fruits that are in season will allow you to buy them at the height of their freshness, flavor, and nutritional value.

"Look for fruits that are firm, don't have soft brown spots or bruises, and are not overly ripe," Al Bochi said, adding that they should not have an odor.

Pears, peaches, plums and other soft fruits should be washed under slightly cool running water and dried with a paper towel before storing or eating.

"You should also wash the peels of bananas, oranges, avocados, and grapefruit with cool tap water as bacteria can transfer from the peel to the edible flesh," Drayer said.

Melons, especially the type that have rough, pocked surfaces such as cantaloupes, should be washed with a vegetable brush under running water and patted dry before storing or eating. Why? Bacteria and other microorganisms can hide in those pits and be transferred to the inside flesh while cutting, or to other veggies and fruits while storing.

The exception to the rule are grapes, cherries and berries.

"Berries should be washed just prior to eating because the moisture can cause them to spoil earlier," Drayer said.

And here's a wrinkle: Some veggies and fruits don't play nicely together. That's because some release ethylene gas as they ripen, which can hurt some other produce.

"For example, apples, avocados, unripe bananas, peaches, nectarines, plums and tomatoes release ethylene gas -- and should not be stored with ethylene-sensitive produce, such as broccoli, Brussels sprouts, ripe bananas, lettuce, peppers, cucumber, eggplant, carrots, cauliflower, and sweet potatoes, as this can speed the decay of the sensitive produce," Dryer said.

Fresh herbs

Look for bright green foliage that isn't wilted. Once home, rinse them under cool water and then lay on paper towels in a single layer to dry. Some suggest using a salad spinner -- but gently.

Storage will depend on whether the herb has a soft or woody stem.

Soft herbs: Treat soft herbs like tarragon, parsley, cilantro, dill and mint like they are fresh flowers. Cut a half-inch off the ends and put the ends down in a jar of water. Cover the jar loosely with a plastic wrap and store in the fridge, changing the water every few days.

Do the same with basil, but store it uncovered on the counter where it can get a bit of light.

Woody herbs: Wrap herbs such as rosemary, thyme, oregano, sage, and chives in wet paper towels and store them in an air-tight container or sealed plastic bag to keep the oxygen out.

Plan ahead

There's one more tip you need to be a star at getting the most out of your produce dollar: Plan your menus for the week in advance.

"Having a general plan of the meals you plan on cooking for the week will help you know what fruits and veggies to buy at the grocery store and help you use up your produce efficiently," Al Bochi said. "You'll reduce food waste and ultimately save money."

Read more:
How to stop throwing away your veggies and fruit - CNN International

Skin Stem Cells Comments Off on How to stop throwing away your veggies and fruit – CNN International | November 12th, 2019

ByKristin Hanson

This article was originally published on Nov. 8 on giving.jhu.edu

Between 2001 and the beginning of 2018, more than 1,500 U.S. military service members lost limbs in the line of duty. Although technology has improved the prosthetic devices these people can use, a stubborn obstacle remains: the fragility of human skin.

"Skin was never meant to hold this kind of pressure," says Lee Childers, the senior scientist for the Extremity Trauma and Amputation Center of Excellence at Brooke Army Medical Center in San Antonio, Texas.

"Think about it like a blister on your foot. It's painful, but you can still get by," he continues. "In an amputation, it's a blister on your residual limb. You can't use your prosthesis until the blister is completely healed. If it's your leg [that is affected], you can't walk for two or three weeks. Think about how that would impact your life."

What if there were a way to make the skin at an amputation site tougher, like the palm of your hand or the sole of your foot? Luis Garza, an associate professor of dermatology at Johns Hopkins and leader of the Veteran Amputee Skin Regeneration Program, is developing a cell therapy that could enable prosthetics wearers to use their devices longer.

"This is an example of personalized medicine," Garza says. "We're taking each person's own cells, growing them up, and inserting them back in."

Garza's postdoctoral research focused on skin stem cells. In 2009, he and his department chair, Sewon Kang, began having conversations about how that work could help the increasing numbers of veterans coming back from war with amputations. Garza and his team received grants from the U.S. Department of Defense, National Institutes of Health, and Maryland Stem Cell Fund that have moved the program forward in the past decade.

Garza's team spent the summer of 2019 testing "normal" subjectsthose without amputationsto perfect the procedure, including the dose, content, method, and frequency of the injections. During one appointment, members of Garza's team took biopsies of skin from a subject's scalp and sole. The cells went to a lab where they were grown under an FDA-approved protocol and passed through quality control tests.

In a second appointment, subjects completed a questionnaire and underwent baseline measurements of their skin's thickness and strength. Garza's team then injected a site on the subjects' skin with the stem cells grown from their cells in the lab.

Image caption: Luis Garza, associate professor of dermatology at Johns Hopkins, leads the Veteran Amputee Skin Regeneration Program.

"We're hoping that these stem cell populations will engraft in the new skin," Garza says.

The subjects returned to Hopkins several months later to go through the questionnaire and measurements once more, and Garza's team documented changes.

Confident in the results they gleaned from the normal subjects, Garza's team enrolled its first subject with an amputation in August. Moving from the normal population to the amputation-affected population quickly unearthed some aspects of the therapy Garza didn't anticipate.

"When we talked with him, he said 'I don't want to mess with my one remaining footdo you have to take skin from there?' And we said, 'Actually, no, we could do your palm,'" Garza says.

His team then tested the biopsy and growth of palm cells from subjects in the normal population. "We're moving away from having our product informed purely by biology to letting our therapy development be shaped by the user."

Although federal grants have supported much of the program's progress, private philanthropy has played a role, too. Corporations like Northrop Grumman, foundations like the Alliance for Veteran Support, and grateful patients with and without ties to the armed forces have contributed nearly $300,000. Those gifts have enabled the program to persevere through gaps between federal grants.

Private funds will be increasingly important as the project enters its next phase: extension to military medical centers around the country. Garza's team must prove that the safeguards to protect cells on their round-trip voyage from a test site to Hopkins are effective. They also must secure approval by local institutional review boards for clinical studies.

"Soldiers are used to getting orders, but you can't order someone to be part of a [medical] study," Garza says. "There are hard medical ethics questions around how to make this open to them but ensure they don't feel obligated. We've been working on that for a year, and we probably have another six months or so to go."

Childers stands ready for whenever the program's extension is a go. He will lead the study at Brooke Army Medical Center and feels motivated by the prospect of helping many of the veterans he works with every day.

"We do everything we can to serve those who serve us. This can enable people to return to duty and be redeployed if they choose," he says. "This is game-changing technology that will have an impact for our service members, but also others who live with amputation."

That population includes the hundreds of thousands of Americans who've undergone amputations for complications of diabetes, who must use a wheelchair, or who wear ankle or foot orthoses for help with walking, among others.

"Having the ability to transform skin anywhere you want to target on the body will have gigantic implications across the entire spectrum of our society in many ways," Childers says.

There's a lot of work to be done before such benefits reach the public, Garza cautions. With continued support from donors and the military community, though, he's optimistic about the program's future.

"The challenges are pretty big, but I think within five years, it could happen," he says. "That's the hope."

Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of the Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force and Department of Defense or the U.S. Government.

Read more:
Serving those who serve - The Hub at Johns Hopkins

Skin Stem Cells Comments Off on Serving those who serve – The Hub at Johns Hopkins | November 11th, 2019

Even though your skin goes through unlimited wear and tear, it is able to repair itself. How does it undertake these regrowth factory activities? There are reservoirs of stem cells within supportive micro-environments, also called niches, throughout the skin. They can keep a tight leash on this repairing process. Too much tissue can lead to complications such as cancer, even though too less may enhance ageing.

Can stem cells direct other stem cells to reform into new skin when they reshape their niches? A study published in Science, led by Prof. Elaine Fuchs actually shows that stem cells have an effect on tissue regeneration. It marks out a molecular coordination tool that can be leveraged by stem cells to convey signals across niches.

The scientists wrote in the abstract of their article, published in Science: "Tissues rely on stem cells (SCs) for homeostasis and wound-repair. SCs reside in specialized microenvironments (niches) whose complexities and roles in orchestrating tissue growth are still unfolding. Here, we identify lymphatic capillaries as critical SC-niche components. In skin, lymphatics form intimate networks around hair follicle (HF) SCs."

Hence, another component of the niche that was revealed was the lymphatic capillaries, specialized types of vessels. They transport immune cells and also drain out excess fluids and toxins from tissues. As the capillaries integrate into a close network around the stem cell niche inside every hair follicle, all the niches get interconnected.

"By turning the skin completely transparent," says postdoctoral fellow Shiri Gur-Cohen, "we were able to reveal the complex architecture of this network of tubes." Researchers identified that the hair-follicle stem cells manage the behavior of lymphatic capillaries. They do this by secreting molecules acting as on-off switches for drainage. They enabled them to monitor the compositions of fluids and cells around them and finally synchronize regeneration across the tissues.

"The involvement of the lymphatic system in this process is a new concept," says Fuchs, "and might potentially provide new therapeutic targets for lymph-related conditions such as wound-healing defects and hair loss." The scientists summarized their findings in Science: "When lymphatics are perturbed or the secretome switch is disrupted, HFs cycle precociously and tissue regeneration becomes asynchronous. In unearthing lymphatic capillaries as a critical SC-niche element, we have learned how SCs coordinate their activity across a tissue."

Hence, to those who haven't understood why they are losing hair in tufts, checking out the scientific experiments on your lymphatic systems can go a long way in figuring out how it can be regrown.

Continue reading here:
Hair regrowth depends on lymphatic system, finds study giving hope to find way to cure baldness - International Business Times, Singapore Edition

Skin Stem Cells Comments Off on Hair regrowth depends on lymphatic system, finds study giving hope to find way to cure baldness – International Business Times, Singapore Edition | November 11th, 2019

NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (KDMN) today announced positive topline results from the planned interim analysis of ROCKstar (KD025-213), the fully enrolled pivotal trial evaluating KD025 in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy. The trial met the primary endpoint of Overall Response Rate (ORR) at the interim analysis, which was conducted as scheduled two months after completion of enrollment.

KD025 showed statistically significant ORRs of 64% with KD025 200 mg once daily (QD) (95% Confidence Interval (CI): 51%, 75%; p<0.0001) and 67% with KD025 200 mg twice daily (BID) (95% CI: 54%, 78%; p<0.0001). KD025 has been well tolerated and adverse events have been consistent with those expected in the patient population.

"We are extremely pleased with the outcomes of the interim analysis, which showed that KD025 has already greatly exceeded the threshold for success in this pivotal trial," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to sharing these results with the FDA at a pre-NDA meeting, where we will also discuss the timing for a regulatory filing for KD025 in cGVHD, which we expect to occur in 2020, subject to FDA input."

"KD025 was shown to be a highly active and well-tolerated therapy across the spectrum of this complex, multi-organ disease," said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School; Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute and a KD025-213 study investigator and Steering Committee member. "The response rates observed are particularly impressive since this study is being conducted in a real-world population with severe disease, supporting the potential role of KD025 in cGVHD patients who are in need of effective and well-tolerated therapies."

"It is highly encouraging to see the positive results from the pivotal trial are in line with those observed in the earlier Phase 2 study of KD025 in this difficult-to-treat disease," said Madan Jagasia, MD, Vanderbilt University, an investigator of the KD025-208 and KD025-213 studies and the KD025-213 Steering Committee chair. "These latest KD025 data continue to underscore the value that KD025 may offer to cGVHD patients."

KD025-213 is an ongoing open-label trial of KD025 in adults and adolescents with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive KD025 200 mg QD or KD025 200 mg BID, enrolling 66 patients per arm. Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%, which was achieved in both arms of the trial at the interim analysis.

While the ORR endpoint was met at the interim analysis, the primary analysis of the KD025-213 study will occur in the first quarter of 2020, six months after completion of enrollment. This analysis will include updated safety data and efficacy data, including ORRs and secondary endpoints, such as duration of response, changes in corticosteroid dose and changes in quality of life. Kadmon plans to submit results from the KD025-213 study for presentation at an upcoming scientific meeting.

Conference Call and Webcast

Kadmon will host a conference call and webcast on Monday, November 11, 2019, at 5:00 p.m., Eastern time, to discuss the topline results of the interim analysis of the KD025-213 study.

To participate in the conference call, please dial (866) 762-3021 (domestic) or (703) 925-2661 (international) and reference the conference ID: 6468498. The accompanying slides will be available for download on Kadmon's website beginning at 5:00 p.m. Eastern time.

To listen online via webcast, please visit: https://edge.media-server.com/mmc/p/9b9w8p38. The webcast will be archived and will be available at http://investors.kadmon.com/presentations-and-events.

About KD025

KD025 is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response. In addition to cGVHD, KD025 is being studied in an ongoing Phase 2 clinical trial in adults with diffuse cutaneous systemic sclerosis (KD025-209). KD025 was granted Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with cGVHD who have received at least two prior lines of systemic therapy.

Story continues

About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD, and approximately 5,000 new patients are diagnosed with cGVHD per year.

About Kadmon

Kadmon is a biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology.

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, including KD025-213, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates, including KD025; (iv) the timing or likelihood of regulatory filings and approvals, including in connection with KD025-213; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; (xxi) the use of proceeds from our recent public offerings; (xxii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiii) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxiv) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in Kadmon's filings with the U.S. Securities and Exchange Commission (the "SEC"), including Kadmon's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Kadmon assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri, Investor Relations646.490.2989ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/566116/Kadmon-Announces-that-KD025-Met-Primary-Endpoint-at-Interim-Analysis-of-Pivotal-Trial-in-Chronic-Graft-Versus-Host-Disease

See the article here:
Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease - Yahoo Finance

Skin Stem Cells Comments Off on Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease – Yahoo Finance | November 11th, 2019

Since 2006, when Shinya Yamanaka, now the director of the Center for iPS Cell Research and Application at Kyoto University, discovered a method that could guide fully differentiated cells back to their pluripotent state, scientists have been using his recipe to produce induced pluripotent stem cells. The protocol relies on overexpressing the so-called Yamanaka factors, which are four transcription factors: Oct4, Sox2, Klf4, and cMyc (OSKM). While the technique reliably creates iPS cells, it can cause unintended effects, some of which can lead to cells to become cancerous. So researchers have worked to adjust the cocktail and understand the function of each factor.

No one had succeeded in creating iPS cells without forcing the overexpression of Oct4. It was thought that this was the most crucial factor of the four. At least until now.

If this works in adult human cells, it will be a huge advantage for the clinical applications of iPS cells.

Shinya Yamanaka, Kyoto University

Four years ago, Sergiy Velychko, a graduate student at the Max Planck Institute for Molecular Biomedicine in Hans Schlers lab, and his team were studying the role of Oct4 in creating iPS cells from mouse embryonic fibroblasts. He used vectors to introduce various mutations of the gene coding for Oct4 to the cells he was studying, along with a negative controlone that didnt deliver any Oct4. He was shocked to discover that even using his negative control, he was able to generate iPS cells.

Velychkos experiment was suggesting that it is possible to develop iPS cells with only SKM.

We just wanted to publish this observation, Velychko tells The Scientist, but he knew hed need to replicate it first because reviewers wouldnt believe it.

He and his colleagues, including Guangming Wu, a senior scientist in the lab, repeated the experiment several times, engineering vectors with different combinations of the four factors. SKMthe combination that didnt include Oct4was able to induce pluripotency in the cells with about 30 percent of the efficiency of OSKM, but the cells were of higher quality, meaning that the researchers didnt see evidence of common off-target epigenetic effects. They reported their results yesterday (November 7) in Cell Stem Cell.

Efficiency is not important. Efficiency means how many colonies do you get, explains Yossi Buganim, a stem cell researcher at the Hebrew University of Jerusalem, who was not involved in the study. If the colony is of low quality, the chances that eventually the differentiated cells will become cancerous is very high.

Finally, the team employed the ultimate test, the tetraploid complementation assay, in which iPS cells are aggregated with early embryos that otherwise would not have been able to form a fully functional embryo on their own. These embryos grew into mouse pups, meaning that the iPS cells the team created were capable of maturing into every type of cell in the animal.

Whats more is they found that the SKM iPS cells could develop into normal mouse pups 20 times more often than the OSKM iPS cells, suggesting that the pluripotency of iPS cells can be greatly improved by omitting Oct4 from the reprogramming factor cocktail.

The results will need to be verified in human cells, Buganim cautions. His team has developed methods for creating iPSCs that worked well in mouse cells only to be completely ineffective in humans.

Yamanaka himself was enthusiastic about the results, telling The Scientist in an email that his team would definitely try the method in other cell types, especially adult human blood cells and skin fibroblasts. If this works in adult human cells, it will be a huge advantage for the clinical applications of iPS cells.

S.Velychkoet al.,Excluding Oct4 from Yamanaka cocktail unleashes the developmental potential of iPSCs,Cell Stem Cell,doi:10.1016/j.stem.2019.10.002,2019.

Emma Yasinski is a Florida-based freelance reporter. Follow her on Twitter@EmmaYas24.

Follow this link:
Oct4, Considered Vital for Creating iPSCs, Actually Isnt Needed - The Scientist

Skin Stem Cells Comments Off on Oct4, Considered Vital for Creating iPSCs, Actually Isnt Needed – The Scientist | November 9th, 2019

Ambrosia Health is back.

Following a brief shuttering and then a rebranding effort during which it was known as Ivy Plasma the young blood clinic has gone back to its roots: selling plasma sourced from the blood of 16- to 25- year-olds to healthy patients who believe the transfusions can give them ill-defined health benefits.

People really like the Ambrosia name and brand, so Ambrosia is going to continue, Ambrosia founder and young blood advocate Jesse Karmazin told OneZero. The resounding response from people wanting to sign up was, keep things the same. So thats what were going to do.

With the return to its original branding, Ambrosia is also embracing a new business model.

When it was Ivy Plasma, the clinic offered transfusions in San Francisco and Tampa. It since shuttered the clinic in Tampa, but Karmazin told Futurism that Ambrosia will ship plasma directly to any customers doctor so they can get their dose of young blood without having to fly to California.

We use overnight shipping to deliver the plasma to patients doctors offices, and provide training for the doctors to infuse it, Karmazin told Futurism last month. This way, the number of patients we are able to serve has increased dramatically. I dont operate a blood bank.

Ambrosias checkered, on-again-off-again status was spurred by an FDA statement issued in February in which the regulatory agency warned that transfusions of young blood didnt have any of the health benefits especially enhanced youthfulness, improved longevity, or reversedmemory loss that advocates claimed it did.

In slightly more words, the FDA essentially called young blood transfusions dangerous scams.

Because of the FDA warning, Karmazins clinic offered off-label treatments when it resurfaced as Ivy Plasma. That meant that customers could get their treatments if they desired, but they did so at their own risk and then-Ivy Plasma wasnt legally permitted to claim it would do them any good.

That practice continues today in the newly rebranded Ambrosia, according to OneZero. But the clinics updated website includes more details about the treatment.

Our treatment has been found to produce statistically significant improvements in biomarkers related to Alzheimers disease, cancer, inflammation, and stem cells in our clinical trial, the website reads. Patients have reported subjective improvements in athletics, memory, skin quality, sleep, and other areas.

When asked whether the FDAs rules had grown more lenient, Karmazin told Futurism he had consulted with the agency as well as a number of lawyers and wasnt worried about the claims made on his website.

Im comfortable with going ahead and offering this treatment commercially to patients, he told OneZero.

Here is the original post:
Ambrosia Is Back to Selling Transfusions of Young People's Blood - Futurism

Skin Stem Cells Comments Off on Ambrosia Is Back to Selling Transfusions of Young People’s Blood – Futurism | November 9th, 2019